Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825043 | 0.92 | GPR84 (0.55) | GPR84 | |
| SCHEMBL17508788 | 0.89 | GPR84 (0.48) | GPR84 | |
| SCHEMBL15825863 | 0.88 | GPR84 (0.50) | GPR84 | |
| SCHEMBL15824547 | 0.88 | GPR84 (0.50) | GPR84 | |
| SCHEMBL15825410 | 0.86 | GPR84 (0.53) | GPR84 | |
| SCHEMBL15822691 | 0.85 | GPR84 (0.50) | GPR84 | |
| SCHEMBL15826519 | 0.85 | GPR84 (0.47) | GPR84 | |
| SCHEMBL15822697 | 0.84 | GPR84 (0.50) | GPR84 | |
| SCHEMBL15825896 | 0.83 | GPR84 (0.35) | GPR84 | |
| SCHEMBL15825861 | 0.83 | GPR84 (0.53) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241068-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2023-08-03 | — | — | US | claimed |
| EP-4186507-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2023-05-31 | — | — | EP | claimed |
| US-20210106582-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2021-04-15 | — | — | US | claimed |
| CN-111343986-A | Compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases | 加拉帕戈斯股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2018-01-18 | — | — | US | claimed |
| US-9708312-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | claimed |
| EP-2935262-B1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | claimed |
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2016-02-11 | — | — | US | claimed |
| EP-4186507-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2023-05-31 | — | — | EP | disclosed |
| US-20210106582-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2021-04-15 | — | — | US | disclosed |
| CN-111343986-A | Compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases | 加拉帕戈斯股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2018-01-18 | — | — | US | disclosed |
| US-9708312-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | disclosed |
| EP-2935262-B1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2016-02-11 | — | — | US | disclosed |
| EP-2935262-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | Galapagos NV (BE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095798-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GPR84, GPR88, GPR65 | GPR84 1/4885 |
| US-20230241068-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GPR84, GPR65, GPR88 | GPR84 1/4885 |
| US-20210106582-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GPR84, GPR65, GPR88 | GPR84 1/4885 |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GPR84, GPR88, GPR65 | GPR84 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.